64 results about "Allogeneic graft" patented technology

There is disclosed a packaged allograft implant configured for implantation in a human recipient. In an embodiment, the packaged allograft implant includes an acellular dermal matrix sheet having a top surface and a bottom surface in opposition to one another, a perimeter surrounding the top surface and the bottom surface, and a thickness extending between the top surface and the bottom surface. The packaged allograft implant further includes a mesh pattern extending across at least a portion of the top surface and the bottom surface of the acellular dermal matrix sheet, the mesh pattern providing through-holes extending between the top surface and the bottom surface of the acellular dermal matrix sheet, and the mesh pattern having a plurality of mesh lines extending in a first direction and a second direction. The first direction and the second direction are orthogonal to one another so as to allow a given amount of stretch in each of the first direction and the second direction. Other embodiments are also disclosed.

Allografts for soft tissue repair, including breast reconstruction and other plastic surgery procedures, are disclosed. In an exemplary embodiment, first and second cuts are made into the reticular layer of a skin sample to separate an improved acellular dermal matrix (ACDM) which forms a dermal tissue form useful as a graft. The dermal tissue form consists essentially of reticular dermis and has a first exposed surface formed by reticular dermis, an opposite second exposed surface formed by reticular dermis, and has substantially uniform density and uniform porosity between the first and second exposed surfaces, which allows and promotes rapid and efficient cellular ingrowth and tissue ingrowth substantially equally from either the first or second exposed surfaces upon implantation.

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein said sample comprises a plurality of nucleic acid (NA) molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising, a processor, and a non-transitory computer readable storage medium encoded with a computer program that causes said processor to providing a sample, wherein said sample comprises a plurality of NA molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof.

The art does not provide systematic and reproducible methods to personalize dosing of multiple immunosuppressive medications after transplantation. This invention provides a method to systematize multi-drug immuno suppression management in tissue and organ transplantation using an artificial intelligence-based complex systems approach. In embodiments of this invention, immunosuppression drug dose, blood drug concentrations, donor-derived fraction of cell free DNA (dd-cfDNA %), and aspartate aminotransferase are used to indicate allograft status or a proxy for allograft status, to generate a phenotypic response surface to produce individual treatment modalities and dosages using empirically determined unique coefficients. This surface is used to calculate appropriate immunosuppression drug doses associated with the desired outcome for that patient. Embodiments of this disclosure are directed to identifying optimized combinations of inputs for the complex system of the immunosuppressed transplant patient in order to avoid transplant rejection while avoiding unnecessary toxicity and maintaining a robust enough immune response to fight infection.

The present disclosure provides methods for determining the status of an allograft within a transplant recipient from genotypic data measured from a mixed sample of DNA comprising DNA from both the transplant recipient and from the donor. The mixed sample of DNA may be preferentially enriched at a plurality of polymorphic loci in a way that minimizes the allelic bias, for example using massively multiplexed targeted PCR.

Embodiments of systems and methods for fixing soft tissue are disclosed herein. In some embodiments, soft tissue may be fixed to an attachment surface (such as bone, other soft tissue, other implants, or allograft or xenograft materials) by providing a helical suture in the soft tissue, wherein the soft tissue has a longitudinal axis along which the soft tissue undergoes tension under normal physiological conditions, and wherein a longitudinal axis of the helical suture in the soft tissue is oriented parallel to the longitudinal axis of the soft tissue; and securing the helical suture to an anchor secured to the attachment surface.

Organ transplantation is currently recognized as the treatment of choice for patients with end-stage renal disease (ESRD). To date, no risk-stratification system exists that adequately predicts transplant patients' individual risk of allograft loss. Described herein the development and validation of an integrative risk prediction score to predict kidney allograft survival of individual patients. A methodology of predicting whether a kidney transplant recipient is at risk of having allograft loss is accomplished by implementing the iBox risk prediction score. The methodology can be achieved using a computer-readable storage medium with program instructions which, when executed by a data-processing unit, cause execution of at least the step of implementing an algorithm of said method of predicting whether a kidney transplant recipient is at risk of having allograft loss.

Improved allografts having controlled and consistent properties and useful for soft tissue repair, including breast reconstruction, and other surgical procedures, are disclosed. In one embodiment, an improved acellular dermal matrix (ADM) is produced from a skin sample, where the ADM consists essentially of a single dermal tissue type (e.g., papillary or reticular) and comprises a collagen matrix having substantially uniform density and porosity. In another embodiment, two ADMs are produced from the same dermal tissue type (e.g., papillary or reticular) of the same skin sample, each of which consists essentially of reticular dermis, and comprises a collagen matrix having substantially uniform density and porosity. All such improved ADMs are suitable for use in breast reconstruction and other tissue repair and modification surgery procedures.

A device and system for inserting and impacting bone dowel allografts or bone chips into a bone tunnel. The surgical impacting system includes a surgical tamp having a proximal end and a distal end with an elongated shaft extending therebetween. The surgical tamp has an inner channel extending therethrough from the proximal end to the distal end. The distal end of the surgical tamp can have a distal tip. The surgical tamp may have a handle at the proximal end or a proximal tip at the proximal end. The surgical tamp may also have one or more slots extending through the exterior surface of the elongated shaft and into the inner channel. The surgical tamp can be configured for insertion into a delivery tube. The delivery tube serves the purpose of containing a bone dowel or bone chips therein for smooth insertion into the joint.

Provided herein are a method of processing human birth tissue to create a variety of tissue forms that maintain high levels of beneficial compounds and increase tissue availability. Also provided are products made from the processed tissue forms, and application of these products in soft tissue repair and the treatment of wounds.

The invention relates to allograft tolerance without systemic immune containment. There is provided a cell genetically modified to comprise at least one mechanism for providing localized immune containment at a transplantation site when transplanted into an allogeneic host; and methods for making and using the cells. The cell comprises a set of transgenes, each transgene encoding a gene product of cytoplasm, membrane binding or topical action, and having one or more of the following functions: mitigating antigen presenting cell activation and function; mitigating leukocyte activity or cytolytic function of the aggressive graft; the cytolytic function and phagocytosis of macrophages of allograft cells are reduced; inducing apoptosis in the graft-attacking leukocytes; reducing local inflammatory proteins; and protecting from leukocyte mediated apoptosis.

Provided herein are a method of processing human birth tissue to create a variety of tissue forms that maintain high levels of beneficial compounds and increase tissue availability. Also provided are products made from the processed tissue forms, and application of these products in soft tissue repair and the treatment of wounds.

Disclosed herein is a device and method for securing soft tissue such as the long head of the biceps tendon (or similar) as well as free grafts or allografts directly to bone. The device is directly crimped to the preferred soft tissue. This is accomplished by the application of a crimping device to the implantable device and application of sufficient force to crimp the implantable device thereby fixing said device to the tissue in question. The complex of the device and the tissue / tendon can then be directly fixed to bone as necessary. Additionally, the same device and method can be used to connect one tendon to another as indicated.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The present application relates to a bifunctional therapeutic substance for treating cancer, comprising a targeting component that targets a tumor-associated antigen and an enzyme that, when delivered to a tumor by the targeting component, converts the tumor phenotype into the phenotype of a mismatched allograft or xenograft. The enzyme is connected to the targeting component. Also disclosed is a method for treating cancer, comprising the step of administering the bifunctional therapeutic substance.

There is disclosed an acellular dermal matrix (ADM) graft stored as a packaged ADM graft pocket product prepared by a process that includes providing a portion of ADM tissue having a thickness between 1 mm and 2 mm. The process includes scoring the portion of the ADM tissue into a pre-defined shape to form the domed shape ADM graft. The process includes verifying the thickness of the domed shape ADM graft; shaping the domed shape ADM graft to form an ADM graft pocket configured to receive a breast implant. The process includes packaging the ADM graft pocket to form a packaged ADM graft pocket. The process includes irradiating the packaged ADM graft pocket to a sterility assurance level of a desired level to form the packaged ADM graft pocket product. Other embodiments are also disclosed.

Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to modify immunosuppressive therapy.

The present invention relates to the use of bone graft particles in the preparation of a porous bone graft material comprising an acid-containing self-setting adhesive composition. The bone graft particles have a porous core, the outer surface of which is at least partially covered by an outer layer. The core comprises a core material selected from the group consisting of a heterograft, a bone xenograft, and a bone allograft, or mixtures thereof. And the outer particle layer comprises carbonate.

The disclosure herein relates to isolated and purified mammalian fetal allografts and kits and compositions containing these. Also disclosed are methods of preparing isolated and purified mammalian fetal allografts; methods of contacting a wound of a subject with these, and methods of treating a disease or condition with these.

An allograft preparation station includes a frame and a cutting guide. The frame includes a pair of outer members and a pair of inner members receivable in respective outer members of the pair of outer members. The pair of inner members, when coupled to the frame, may be adjusted to grip a bone from opposing sides of the bone. The cutting guide may be separately secured to the bone to guide cutting of the bone in order to extract an allograft from the bone.

Provided herein are formulations for treating bone graft materials prior to implantation. Treating the bone graft materials with the formulations disclosed herein can restore the physiological and biochemical characteristics of bone. The bone graft can be a bone allograft. Also provided herein are methods for preparing the formulations and methods for preparing a bone graft for transplantation.

The present application relates to a bifunctional therapeutic agent for the treatment of cancer, the bifunctional therapeutic agent comprising: a targeting component that targets a tumor-associated antigen; and an enzyme that, when delivered to a tumor by the targeting component, converts a tumor phenotype to a phenotype of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bifunctional therapeutic agent.

The invention features compositions and methods for treating transplant recipients (e.g., chronic allograft rejection) using a senolytic agent and an angiotensin II receptor antagonist or using a senolytic agent and senomorphic agent. The methods and compositions are useful in a variety of transplant settings including, without limitation, solid organ transplants including kidney, lung, heart, liver, intestine, or pancreas transplantation procedures and cellular transplants including but not limited to bone marrow transplants.

Provided is a cell that is genetically modified to include at least one mechanism for providing local immunosuppression at the transplant site when transplanted into an allogeneic host; and methods for preparing and using the cell. The cell comprises a set of transgenes, each of which encodes a gene product that is cytoplasmic, membrane-bound or locally acting, and whose function is one or more of the following: reducing antigen presenting cell activation and function; reducing leukocyte activity or cytolytic function that attacks the graft; reducing macrophage cytolytic function and phagocytosis of allogeneic graft cells; inducing apoptosis in leukocytes that attack the graft; reducing local inflammatory proteins; and protecting against leukocyte-mediated apoptosis. The transgenes include two or more of the following genes: PD-L1, HLA-G or H2-M3, Cd47, Cd200, FASLG or Fasl, Ccl21 or Ccl21b, Mfge8, and Serpin B9 or Spi6.

Methods of extracting bone and / or cellular material from a patient for possible use in a later surgical procedure, which involves that patient or even a different patient, are provided. An embodiment of the method generally comprises extracting bone and / or cellular material from a patient undergoing a routine surgical procedure, saving the material, and then sending it to a storage, separation, and processing facility (e.g., a “biobank”) for use in a later surgical procedure involving that patient, or a different patient. The material may be cancellous bone, cortical bone chips, or bone marrow. The extracted bone and / or cellular material can be processed at the biobank and used in a multitude of different medical procedures (e.g., as an allograft infused with stem cells for use in a fusion procedure).

Disclosed herein are methods of treating a disease selected from the group consisting of graft versus host disease (GVHD), systemic sclerosis (scleroderma), chronic lung allograft dysfunction (CLAD), restrictive allograft syndrome (RAS), and obliterated bronchitis syndrome (BOS), using a combination of a BTK inhibitor, such as rezobrutinib, and besudil.

Systems and methods for bone reconstruction. In some implementations the systems and methods may be used to remove and replace a bone portion with an implant, which may be an allograft, biomaterial, metal implant, or any other type of implant. The systems and methods may be used to make accurate cuts in bone to remove a diseased bone portion and then reproduce the cuts in a donor material to recreate the precise geometry of the removed portion. Additionally or alternatively, the system can check the accuracy of reconstruction when a segment of bone is replaced.

The present invention provides bone grafts, such as allografts, and methods of releasing growth factors from tissues with native living cells, such as bone marrow, bone matrix, adventitia and / or inventitia. Also provided are compositions comprising growth factors and uses of the compositions to improve osteoinductivity of implants, such as bone grafts.